In the CLEOPATRA trial, HER2-positive advanced breast cancer patients treated with the combination of trastuzumab, pertuzumab, and docetaxel had a median overall survival (mOS) of 56.5 months, compared to 40.8 months reported in patients treated with trastuzumab and docetaxel (93, 94). Here, ERBB2 is linked to breast cancer.